Clinical Trials
15 trialsNCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of AvastinĀ® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT07481786 2026-04-06
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Sun Yat-sen University
Phase 3 Recruiting
NCT06888817 2026-02-25
BRAINS
The Netherlands Cancer Institute
Phase 3 Recruiting
NCT01951482 2025-08-17
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3 Completed
NCT06471465 2025-08-17
BRADI
Institut Cancerologie de l'Ouest
Phase 3 Recruiting
NCT02017717 2025-04-04
CheckMate 143
Bristol-Myers Squibb
Phase 3 Completed
NCT05118776 2024-10-31
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Ascletis Pharma Inc
Phase 3 Active not recruiting
NCT05271240 2024-09-19
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
Phase 3 Recruiting
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT05718466 2023-07-17
Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Henry Ford Health System
Phase 3 Completed
NCT02761070 2023-03-08
RE-GEND
Kyorin University
Phase 3 Unknown
NCT01290939 2021-02-15
Bevacizumab and Lomustine for Recurrent GBM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00884741 2019-07-24
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT02511405 2018-10-23
GLOBE
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 3 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (AvastinĀ®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed